son-1010
Generic: Interleukin 12 (IL-12)·Code: SON-1010
son-1010: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SONNET BIOTHERAPEUTICS HOLDINGS, INC. (BURG) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Adult Patients With Advanced Solid Tumors.
Frequently asked questions
Who is developing son-1010?
son-1010 is being developed by SONNET BIOTHERAPEUTICS HOLDINGS, INC..
How many clinical trials involve son-1010?
BioSniper tracks 1 clinical trial involving son-1010.
Get deeper analysis on son-1010
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis